

Express Mailing Label No. EJ69 6847US  
Date of Deposit: September 28, 1999



1-27  
#11

**PATENT APPLICATION**  
Attorney Docket No. 00960-515 (CRP-145)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS : Cohen, *et al.*  
ASSIGNEE : Creative BioMolecules, Inc.  
SERIAL NUMBER : 08/851,628 EXAMINER : Romeo, D.  
FILING DATE : May 6, 1997 ART UNIT : 1646  
FOR : NOVEL THERAPIES FOR CHRONIC RENAL FAILURE

Assistant Commissioner for Patents  
Washington, D.C. 20231

**REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY**

CREATIVE BIOMOLECULES, INC., a company and owner of the above-identified United States patent application U.S.S.N. 08/851,628, filed May 6, 1997, assignment recorded on November 28, 1997, at Reel 8827/Frame 0589, hereby revokes any and all former powers of attorney and appoints:

Attorney or Agent	Registration No.	Attorney or Agent	Registration No.
David B. Bernstein	32,112✓	John T. Prince	43,091✓
David F. Crosby	36,400✓	Brian Rosenbloom	41,276✓
Brett N. Dorny	35,860	Thomas M. Sullivan	39,392✓
Ivor R. Elrifi	39,529	Howard Susser	33,556✓
John A. Harre	37,345✓	Martin M. Zoltick	35,745
William Marino	44,219✓	Kristin E. Konzak	P-44,848✓
Leslie Meyer-Leon	37,381✓	Carol H. Peters	P-45,010✓
A. Jason Mirabito	28,161✓	Garfield B. Simms	P-45,109✓
Michel Morency	Limited Recognition	Shelby J. Walker	P-45,192✓

all of MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO PC, One Financial Center, Boston, Massachusetts 02111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the above-identified patent.

APPLICATION NO.

08/851,628

APPLICANTS:

Cohen, et al.

SEND CORRESPONDENCE TO:

Ivor R. Elrifi  
Mintz Levin  
One Financial Center  
Boston, MA 02111

DIRECT TELEPHONE CALLS TO:

Ivor R. Elrifi, or  
Michel Morency  
(617) 542-6000

CREATIVE BIOMOLECULES, INC. certifies under 37 C.F.R. § 3.73(b) that it is the Assignee of the entire right, title and interest in the patent identified above by virtue of assignments of the above identified patent.

I, the undersigned, am empowered to act on behalf of the Assignee. Acting on behalf of the Assignee, I have reviewed all the documents in the chain of title of the patent identified above and, to the best of my knowledge and belief, title is in the Assignee identified above.

I, the undersigned, hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the patent.

Please charge any fee or any fee deficiency occasioned by this document to Deposit Account No. 50-0311.

Respectfully submitted,



Cheryl Lawton  
Vice President, General Counsel  
CREATIVE BIOMOLECULES, INC.

Date: <sup>Spt.</sup>~~August~~ 10, 1999

TRADOCS: 1235307.1 (qh6301!.doc)



MAY 24 1999


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATE PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)**

Michel Morency is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. to prepare and prosecute patent applications wherein (1) Michel Morency represents only clients of the Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. law firm, and (2) wherein a member of the Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. law firm who, in turn, is a registered patent attorney or agent, is the attorney or agent of record in the applications. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Michel Morency ceases to lawfully reside in the United States, (ii) Michel Morency's employment with Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C. ceases or is terminated, or (iii) Michel Morency ceases to remain or reside in the United States on H-1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

**Expires: January 1, 2000**

  
\_\_\_\_\_  
Karen L. Bovard, Director  
Office of Enrollment and Discipline

Express Mailing Label No. EJ695376847US  
Attorney Reference No. 00960-515 (CRP-145)